Search
Oxitriptan
go.drugbank.com/drugs/DB02959ApprovedInvestigationalNutraceuticalWithdrawnnaturally occurring amino acid and metabolic intermediate in the synthesis of serotonin and melatonin. 5-HTP is sold over-the-counter in the United Kingdom, United States and Canada as a dietary supplement for … use as an antidepressant, appetite suppressant, and sleep aid, and is also marketed in many European countries for the indication of major depression under trade names like Cincofarm, Levothym, Levotonine
Relebactam
go.drugbank.com/drugs/DB12377ApprovedInvestigationalRelebactam is a diazabicyclooctane beta-lactamase inhibitor, similar in structure to avibactam. It includes a piperidine ring which reduces export from bacterial cells by producing a positive charge. It is currently available in a combin...
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseElotuzumab
go.drugbank.com/drugs/DB06317ApprovedInvestigationalElotuzumab has a theoretical mass of 148.1 kDa for the intact antibody. Elotuzumab was approved on November 30, 2015 by the U.S. Food and Drug Administration. … Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received
Rozanolixizumab
go.drugbank.com/drugs/DB14919ApprovedInvestigational[L47122] In June 2023, Rozanolixizumab-noli was approved by the FDA under Priority Review for the treatment of adult patients with generalized myasthenia gravis who are positive for the anti-acetylcholine … [A260177] It is investigated for use in autoimmune and alloimmune diseases with pathologic IgG, particularly generalized myasthenia gravis.
Tasimelteon
go.drugbank.com/drugs/DB09071ApprovedInvestigationalTasimelteon is a selective dual melatonin receptor agonist indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (N24HSWD). … Tasimelteon is currently the only drug available for the treatment of N24HSWD and was granted orphan drug status by the FDA in 2010.
ISIS 113715
go.drugbank.com/drugs/DB05506InvestigationalISIS 113715 is our second-generation antisense inhibitor of protein tyrosine phosphatase 1b, or PTP‑1b, for the treatment of type 2 diabetes.
Imlifidase
go.drugbank.com/drugs/DB15258ApprovedInvestigationalChronic kidney disease (CKD) is a progressive and irreversible disease that represents a significant burden for both the individual and healthcare system at large. … [A225916] Currently available treatments for end-stage renal disease are limited to dialysis and renal transplantation, with the former associated with significant costs and lower quality of life.
Carindacillin
go.drugbank.com/drugs/DB09319ApprovedWithdrawnCarindacillin or Carbenicillin isdanyl was an oral penicillin prodrug of carbenicillin marketed by Pfizer as Geocillin. It is no longer marketed in the United States.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseNAV 1800
go.drugbank.com/drugs/DB05437ExperimentalRIGScan CR49, a 125I-labelled CR monoclonal antibody directed against the tumour-associated antigen TAG-72, is undergoing development with Neoprobe for the intraoperative detection of metastatic colorectal
Aprocitentan
go.drugbank.com/drugs/DB15059ApprovedInvestigationalEndothelin receptor antagonism provides a novel therapeutic pathway for the management of patients with resistant hypertension. … Aprocitentan is a dual antagonist of endothelin receptors A and B used for treatment-resistant hypertension. It is the active metabolite of [macitentan].